Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bristol's HCV Bump Catalyzes Strong Quarter, But Not Expected To Last

Executive Summary

Daklinza has been part of the standard of care in genotype 3 HCV, but the launch of Gilead's Epclusa and an EU ramp-up of Merck's Zepatier are expected to erode that over time.


Related Content

Bristol Stresses Cost Control Despite Strong Earnings Quarter
Will Real-World Data Sway Course Of Novel Anticoagulant Market?
Gilead Sees Prospects For Declining HCV Revenues To Stabilize
Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy
NICE Reverses Stance On BMS' HCV Pill Daklinza
Success Of Bristol’s Daklinza In Europe May Be Tied To Fate Of Sovaldi


Related Companies